Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Akero Therapeutics Inc (AKRO)

Akero Therapeutics Inc (AKRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,047,903
  • Shares Outstanding, K 69,799
  • Annual Sales, $ 0 K
  • Annual Income, $ -151,760 K
  • EBIT $ -269 M
  • EBITDA $ -278 M
  • 60-Month Beta -0.23
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.67

Options Overview Details

View History
  • Implied Volatility 107.30% ( +16.10%)
  • Historical Volatility 53.03%
  • IV Percentile 90%
  • IV Rank 56.16%
  • IV High 170.21% on 03/01/24
  • IV Low 26.69% on 08/16/24
  • Put/Call Vol Ratio 0.05
  • Today's Volume 44
  • Volume Avg (30-Day) 179
  • Put/Call OI Ratio 0.92
  • Today's Open Interest 15,005
  • Open Int (30-Day) 13,503

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.14
  • Number of Estimates 5
  • High Estimate -1.09
  • Low Estimate -1.19
  • Prior Year -0.99
  • Growth Rate Est. (year over year) -15.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.35 +7.28%
on 12/19/24
33.30 -11.89%
on 11/25/24
-1.30 (-4.23%)
since 11/20/24
3-Month
26.46 +10.88%
on 10/07/24
35.88 -18.22%
on 11/07/24
+1.26 (+4.49%)
since 09/20/24
52-Week
15.32 +91.51%
on 02/06/24
37.00 -20.70%
on 03/04/24
+7.78 (+36.09%)
since 12/20/23

Most Recent Stories

More News
Insider Sale: Chief Scientific Officer of $AKRO (AKRO) Sells 2,450 Shares

Timothy Rolph, the Chief Scientific Officer of $AKRO ($AKRO), sold 2,450 shares of the company on 12-10-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 1.4%...

AKRO : 29.34 (+3.31%)
Insider Sale: Senior VP of $AKRO (AKRO) Sells 925 Shares

Patrick Lamy, the Senior VP of $AKRO ($AKRO), sold 925 shares of the company on 12-10-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 4.9% of their shares....

AKRO : 29.34 (+3.31%)
Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference

AKRO : 29.34 (+3.31%)
Akero Therapeutics Reports Positive Results for Efruxifermin in Treating Metabolic Dysfunction-Associated Steatohepatitis at AASLD Liver Meeting 2024

Over 40% of EFX 50mg participants experienced liver fibrosis regression after 96 weeks, demonstrating significant clinical efficacy.Quiver AI SummaryAkero Therapeutics announced promising results from...

AKRO : 29.34 (+3.31%)
Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024

AKRO : 29.34 (+3.31%)
Akero Therapeutics to Present at the Jefferies London Healthcare Conference

AKRO : 29.34 (+3.31%)
Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

AKRO : 29.34 (+3.31%)
Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024

AKRO : 29.34 (+3.31%)
SGMT Stock Up 12.6% on FDA Fast Track for Liver Disease Drug

Sagimet Biosciences’ SGMT stock rose 12.6% on Tuesday after it announced that the FDA has granted breakthrough therapy designation (“BTD”) to its lead pipeline candidate, denifanstat, for treating...

VKTX : 42.25 (+1.83%)
MDGL : 308.44 (+5.12%)
AKRO : 29.34 (+3.31%)
SGMT : 4.95 (-2.37%)
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024

Stocks that traded heavily or had substantial price changes on Monday: Macy’s, United Rentals rise; Apple, Spirit Airlines fall

SMCI : 31.59 (+1.12%)
SAVE : 1.0800 (-18.18%)
BLKB : 76.31 (+0.16%)
URI : 722.64 (+1.65%)
AKRO : 29.34 (+3.31%)
M : 16.24 (+2.46%)
AAPL : 254.49 (+1.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Akero Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing transformational treatments for non-alcoholic steatohepatitis and other serious metabolic disorders. The company's product pipeline consists of AKR-001, for the treatment of non-alcoholic steatohepatitis, which...

See More

Key Turning Points

3rd Resistance Point 31.72
2nd Resistance Point 30.75
1st Resistance Point 30.04
Last Price 29.34
1st Support Level 28.36
2nd Support Level 27.39
3rd Support Level 26.68

See More

52-Week High 37.00
Last Price 29.34
Fibonacci 61.8% 28.72
Fibonacci 50% 26.16
Fibonacci 38.2% 23.60
52-Week Low 15.32

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar